Condition: Hypertension (HTN) · Sponsor: Novartis Pharmaceuticals
The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| NICRs Research Center | Garden Grove, California, United States | Recruiting |
| Downtown L A Research Center Inc | Los Angeles, California, United States | Recruiting |
| Entrust Clinical Research | Miami, Florida, United States | Recruiting |
| Inpatient Research Clinical LLC | Miami Lakes, Florida, United States | Recruiting |
| Cardiology Partners Clinical Research Institute | Wellington, Florida, United States | Recruiting |
| Javara Research | Fayetteville, Georgia, United States | Recruiting |
| Anderson Medical Research | Ft. Washington, Maryland, United States | Recruiting |
| Jefferson City Medical Group | Jefferson City, Missouri, United States | Recruiting |
| Monroe Biomedical Research | Monroe, North Carolina, United States | Recruiting |
| Novartis Investigative Site | Suita, Osaka, Japan | Recruiting |
| Novartis Investigative Site | Shinjuku Ku, Tokyo, Japan | Recruiting |
| Novartis Investigative Site | Singapore, Singapore | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07543120